Phage-based therapy against biofilm producers in gram-negative ESKAPE pathogens

Microb Pathog. 2023 May:178:106064. doi: 10.1016/j.micpath.2023.106064. Epub 2023 Mar 9.

Abstract

Persistent antibiotic use results in the rise of antimicrobial resistance with limited or no choice for multidrug-resistant (MDR) and extensively drug resistant (XDR) bacteria. This necessitates a need for alternative therapy to effectively combat clinical pathogens that are resistant to last resort antibiotics. The study investigates hospital sewage as a potential source of bacteriophages to control resistant bacterial pathogens. Eighty-one samples were screened for phages against selected clinical pathogens. Totally, 10 phages were isolated against A. baumannii, 5 phages against K. pneumoniae, and 16 phages were obtained against P. aeruginosa. The novel phages were observed to be strain-specific with complete bacterial growth inhibition of up to 6 h as monotherapy without antibiotics. Phage plus colistin combinations reduced the minimum-biofilm eradication concentration of colistin up to 16 folds. Notably, a cocktail of phages exhibited maximum efficacy with complete killing at 0.5-1 μg/ml colistin concentrations. Thus, phages specific to clinical strains have a higher edge in treating nosocomial pathogens with their proven anti-biofilm efficacy. In addition, analysis of phage genomes revealed close phylogenetic relations with phages reported from Europe, China, and other neighbouring countries. This study serves as a reference and can be extended to other antibiotics and phage types to assess optimum synergistic combinations to combat various drug resistant pathogens in the ongoing AMR crisis.

Keywords: Antimicrobial resistance; Bacteriophage; Biofilms; Colistin; Combination therapy; Hospital sewage.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Bacteria
  • Bacteriophages* / genetics
  • Colistin / pharmacology
  • Phage Therapy*
  • Phylogeny

Substances

  • Colistin
  • Anti-Bacterial Agents